Share-based Payment Arrangement, Expense of Landos Biopharma, Inc. from 31 Dec 2020 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Landos Biopharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 31 Mar 2024.
  • Landos Biopharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2024 was $260,000, a 16% increase year-over-year.
  • Landos Biopharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2024 was $1,007,000, a 20% decline year-over-year.
  • Landos Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $971,000, a 51% decline from 2022.
  • Landos Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1,971,000, a 52% decline from 2021.
  • Landos Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $4,118,000, a 394% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Landos Biopharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $1,007,000 $260,000 +$36,000 +16% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $971,000 $245,000 +$49,000 +25% 01 Oct 2023 31 Dec 2023 10-K 21 Mar 2024 2023 Q4
Q3 2023 $922,000 $248,000 +$48,000 +24% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $874,000 $254,000 -$380,000 -60% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $1,254,000 $224,000 -$717,000 -76% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $1,971,000 $196,000 -$2,232,000 -92% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 Q4
Q3 2022 $4,203,000 $200,000 -$155,000 -44% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $4,358,000 $634,000 +$322,000 +103% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $4,036,000 $941,000 -$82,000 -8% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $4,118,000 $2,428,000 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 Q4
Q3 2021 $355,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $312,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $1,023,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1

Landos Biopharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $971,000 -$1,000,000 -51% 01 Jan 2023 31 Dec 2023 10-K 21 Mar 2024 2023 FY
2022 $1,971,000 -$2,147,000 -52% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $4,118,000 +$3,285,000 +394% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $833,000 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.